Lista de obras - Peter Bossuyt - Dominio Público Uruguay

Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study

artículo científico publicado en 2020

Author Correction: Head-to-head trials in inflammatory bowel disease: past, present and future

scientific article published on 05 January 2021

Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density

artículo científico publicado en 2020

Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD)

Belgian recommendations for the management of anemia in patients with inflammatory bowel disease.

artículo científico publicado en 2014

Buried bumper syndrome: single-step endoscopic management and replacement

artículo científico publicado en 2014

Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents

artículo científico publicado en 2015

Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades

artículo científico publicado en 2019

Colonic obstruction in a 45 year old female

artículo científico publicado en 2014

Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection.

artículo científico publicado en 2009

Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease

artículo científico publicado en 2016

Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease

artículo científico publicado en 2020

Defining Endoscopic Remission in Ileocolonic Crohn's Disease: Let's Start from Scratch

artículo científico publicado en 2018

Diffusion-weighted MRI in inflammatory bowel disease

artículo científico publicado en 2018

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

artículo científico publicado en 2019

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

artículo científico publicado en 2017

Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study

artículo científico publicado en 2018

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab

Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists.

artículo científico publicado en 2017

Endoscopic removal of a transgastric eroded laparoscopic adjustable silicone gastric band

artículo científico publicado en 2014

Endoscopic treatment of large symptomatic colon lipomas: A systematic review of efficacy and safety

scientific article published on 03 August 2020

European evidence based consensus for endoscopy in inflammatory bowel disease

artículo científico publicado en 2013

Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease

scientific article published on 15 April 2019

Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice

scholarly article by Catherine Reenaers et al published October 2018 in United European gastroenterology journal

Head-to-head trials in inflammatory bowel disease: past, present and future

artículo científico publicado en 2020

Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study

artículo científico publicado en 2017

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, or Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.

artículo científico publicado en 2018

Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO).

artículo científico

Management of patients with inflammatory bowel disease and spondyloarthritis

artículo científico publicado en 2017

Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab

article

Paediatric Crohn Disease: Disease Activity and Growth in the BELCRO Cohort After 3 Years Follow-up

artículo científico publicado en 2016

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

artículo científico publicado en 2017

Prime Time Was Yesterday for Patient-reported Outcomes in Daily Care of Patients With Inflammatory Bowel Diseases

artículo científico publicado en 2018

Primetime for e-health in IBD?

scientific article published on 25 January 2017

Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk Model

artículo científico publicado en 2017

Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn's Disease

artículo científico publicado en 2015

Scoring endoscopic disease activity in IBD: artificial intelligence sees more and better than we do

artículo científico publicado en 2019

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

artículo científico publicado en 2018

Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?

artículo científico publicado en 2018

Single-centre experience on use of videocapsule endoscopy for obscure gastrointestinal bleeding in 120 consecutive patients

artículo científico publicado el 1 de septiembre de 2011

Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach!

artículo científico publicado en 2018

The course of anaemia in children and adolescents with Crohn's disease included in a prospective registry

artículo científico publicado en 2014

The operative risk and natural history after the diagnosis of ileal penetrating Crohn's disease

artículo científico publicado en 2018

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

scientific article published on 08 July 2019

Treat to Target in Inflammatory Bowel Disease.

artículo científico publicado en 2016

Wandering spleen on a 68Ga-DOTATOC-PET/CT scan

artículo científico publicado en 2011

Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.

artículo científico publicado en 2014

Lista de obras de Peter Bossuyt

Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study

Author Correction: Head-to-head trials in inflammatory bowel disease: past, present and future

Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density

Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD)

Belgian recommendations for the management of anemia in patients with inflammatory bowel disease.

Buried bumper syndrome: single-step endoscopic management and replacement

Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents

Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades

Colonic obstruction in a 45 year old female

Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection.

Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease

Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease

Defining Endoscopic Remission in Ileocolonic Crohn's Disease: Let's Start from Scratch

Diffusion-weighted MRI in inflammatory bowel disease

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab

Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists.

Endoscopic removal of a transgastric eroded laparoscopic adjustable silicone gastric band

Endoscopic treatment of large symptomatic colon lipomas: A systematic review of efficacy and safety

European evidence based consensus for endoscopy in inflammatory bowel disease

Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease

Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice

Head-to-head trials in inflammatory bowel disease: past, present and future

Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, or Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.

Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO).

Management of patients with inflammatory bowel disease and spondyloarthritis

Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab

Paediatric Crohn Disease: Disease Activity and Growth in the BELCRO Cohort After 3 Years Follow-up

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

Prime Time Was Yesterday for Patient-reported Outcomes in Daily Care of Patients With Inflammatory Bowel Diseases

Primetime for e-health in IBD?

Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk Model

Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn's Disease

Scoring endoscopic disease activity in IBD: artificial intelligence sees more and better than we do

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?

Single-centre experience on use of videocapsule endoscopy for obscure gastrointestinal bleeding in 120 consecutive patients

Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach!

The course of anaemia in children and adolescents with Crohn's disease included in a prospective registry

The operative risk and natural history after the diagnosis of ileal penetrating Crohn's disease

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Treat to Target in Inflammatory Bowel Disease.

Wandering spleen on a 68Ga-DOTATOC-PET/CT scan

Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.